ZA200402319B - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer. - Google Patents

Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer.

Info

Publication number
ZA200402319B
ZA200402319B ZA200402319A ZA200402319A ZA200402319B ZA 200402319 B ZA200402319 B ZA 200402319B ZA 200402319 A ZA200402319 A ZA 200402319A ZA 200402319 A ZA200402319 A ZA 200402319A ZA 200402319 B ZA200402319 B ZA 200402319B
Authority
ZA
South Africa
Prior art keywords
proaerolysin
treatment
methods
prostate cancer
containing protease
Prior art date
Application number
ZA200402319A
Other languages
English (en)
Inventor
Samuel R Denmeade
James Thomas Buckley
John T Isaacs
Original Assignee
Univ Victoria Innovat Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Victoria Innovat Dev filed Critical Univ Victoria Innovat Dev
Publication of ZA200402319B publication Critical patent/ZA200402319B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal protein (delta-endotoxin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
ZA200402319A 2001-08-24 2004-03-23 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer. ZA200402319B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31461301P 2001-08-24 2001-08-24

Publications (1)

Publication Number Publication Date
ZA200402319B true ZA200402319B (en) 2005-08-30

Family

ID=23220660

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200402319A ZA200402319B (en) 2001-08-24 2004-03-23 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer.

Country Status (12)

Country Link
US (3) US7282476B2 (zh)
EP (2) EP2518142B1 (zh)
JP (1) JP4319908B2 (zh)
CN (1) CN100488981C (zh)
AU (1) AU2002331720B2 (zh)
CA (1) CA2457903C (zh)
DK (1) DK1567641T3 (zh)
ES (2) ES2388170T3 (zh)
HK (1) HK1178563A1 (zh)
PT (1) PT1567641E (zh)
WO (1) WO2003018611A2 (zh)
ZA (1) ZA200402319B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265866A1 (en) * 2002-09-03 2004-03-29 Vit Lauermann Targeted release
US20060159687A1 (en) * 2003-03-03 2006-07-20 Buckley J T Modified aerolysin and methods of use for treating lung cancer
CA2547034C (en) 2003-11-28 2014-02-18 National Research Council Of Canada Anticarcinoma antibodies and uses thereof
AU2006257664B2 (en) 2005-06-14 2013-01-10 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
EP2386639A3 (en) 2005-11-21 2012-05-30 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
WO2008011157A2 (en) 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
EP2376104A4 (en) 2008-12-15 2014-09-10 Protox Therapeutics Inc Method of treating prostatitis with proaeryslyin, modified pore-forming protein
BR112012010985A2 (pt) 2009-11-09 2016-11-29 Alexion Pharma Inc reagentes e métodos para detectar células sanguíneas tipo ii de hpn e sua identificação como fatores de risco para transtornos trombóticos
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2012054929A2 (en) * 2010-10-22 2012-04-26 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
WO2014160037A2 (en) 2013-03-14 2014-10-02 The Regents Of The University Of California Activatable membrane-interacting peptides and methods of use
TN2016000137A1 (en) 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
WO2015061573A1 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compounds that bind to human immunodeficiency virus rev response element
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10596226B2 (en) * 2015-01-16 2020-03-24 The Johns Hopkins University Albumin-proaerolysin prodrugs
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20170333521A1 (en) * 2016-01-27 2017-11-23 Sophiris Bio Inc. Method for targeted intraprostatic administration of prx302 for treatment of prostate cancer
CN109790206A (zh) * 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2018347796A1 (en) 2017-10-10 2020-05-07 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
KR20220153011A (ko) * 2020-02-03 2022-11-17 프레마스 바이오테크 프라이빗 리미티드 난발현 단백질(dte-p)의 발현을 위한 재조합 발현 플랫폼, 구축물 및 방법
US11845779B2 (en) * 2020-10-28 2023-12-19 Ecole Polytechnique Federale De Lausanne (Epfl) Mutant aerolysin and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5264550A (en) 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
JPH09500102A (ja) 1993-04-28 1997-01-07 ウォーセスター ファウンデーション フォー エクスペリメンタル バイオロジー 細胞指向性溶解孔形成剤
US5777078A (en) 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
ATE293686T1 (de) 1993-06-04 2005-05-15 Us Navy Verfahren zur selektiven stimulierung der t- zellproliferation.
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
AU695618B2 (en) 1994-04-11 1998-08-20 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6066319A (en) 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5798218A (en) * 1996-09-24 1998-08-25 University Of British Columbia Innovation And Development Corporation Compositions and methods for the specific detection of thy-1 antigen
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2271291A1 (en) * 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
WO1998041240A1 (en) 1997-03-14 1998-09-24 The Children's Hospital Of Philadelphia Methods and compositions for use in gene therapy for treatment of hemophilia
US6504014B1 (en) * 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6545131B1 (en) * 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
US6265540B1 (en) * 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
ATE256473T1 (de) 1997-07-10 2004-01-15 Merck & Co Inc Konjugate welche bei der behandlung von prostatakrebs nützlich sind
HUP0003194A3 (en) * 1997-08-15 2003-03-28 Cephalon Inc West Chester Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
WO1999036778A1 (en) * 1998-01-20 1999-07-22 University Of Victoria Innovation & Development Corporation Detection of gpi anchored proteins
US6180356B1 (en) * 1998-03-06 2001-01-30 The Research Foundation Of State University Of Ny Membrane pore inhibiting agents for treating infection
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
AU5122700A (en) * 1999-04-09 2000-11-14 Johns Hopkins University, The Channel forming toxins as antiviral agents
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
EP1052287A3 (en) 1999-05-10 2003-07-09 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
EP1052288A1 (en) 1999-05-10 2000-11-15 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
AU7627200A (en) 1999-07-29 2001-02-19 Johns Hopkins University, The Activation of peptide prodrugs by hk2
US7053042B1 (en) * 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
WO2001027303A1 (en) 1999-10-12 2001-04-19 The University Of North Carolina At Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
MXPA02004349A (es) * 1999-11-01 2003-09-22 Alcon Inc Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma de xantano.
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
FI116467B (fi) 2000-09-29 2005-11-30 Licentia Oy Uudet peptidiligandit
AU2002223316A1 (en) * 2000-11-07 2002-05-21 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
WO2002043773A2 (en) 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
US7456146B2 (en) 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs

Also Published As

Publication number Publication date
US7282476B2 (en) 2007-10-16
CA2457903C (en) 2018-04-17
JP2005520490A (ja) 2005-07-14
US7745395B2 (en) 2010-06-29
US20080089869A1 (en) 2008-04-17
CN100488981C (zh) 2009-05-20
ES2388170T3 (es) 2012-10-09
WO2003018611A3 (en) 2005-06-30
CA2457903A1 (en) 2003-03-06
WO2003018611A2 (en) 2003-03-06
JP4319908B2 (ja) 2009-08-26
EP2518142B1 (en) 2015-07-15
US7838266B2 (en) 2010-11-23
DK1567641T3 (da) 2012-08-27
ES2542888T3 (es) 2015-08-12
HK1178563A1 (zh) 2013-09-13
EP2518142A1 (en) 2012-10-31
EP1567641A2 (en) 2005-08-31
US20100234300A1 (en) 2010-09-16
EP1567641B1 (en) 2012-05-23
AU2002331720B2 (en) 2007-10-11
PT1567641E (pt) 2012-08-21
CN1636017A (zh) 2005-07-06
US20040235095A1 (en) 2004-11-25
EP1567641A4 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
HK1178563A1 (zh) 含有蛋白酶啟動序列的氣單胞菌溶素原及其在前列腺癌治療中的使用方法
IL251270A0 (en) Cancer treatment
EP1515982A4 (en) METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
IL158273A0 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2001276039A1 (en) Methods and apparatus for brachytherapy treatment of prostate disease
HK1080840A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
IL159887A0 (en) Combination therapy for the treatment of cancer
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
AU7129700A (en) Ovarian tumor sequences and methods of use therefor
MXPA03007036A (es) Metodo de terapia para cancer.
GB2389532C (en) The method of treating cancer
GB0124124D0 (en) Methods of treatment
AU2001241779A1 (en) Method of treatment of prostate cancer
EP1409734A4 (en) DIAGNOSIS AND TREATMENT OF CANCER
EP1250145A4 (en) PEPTIDES DERIVED FROM ONCOGENE C-SKI FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
AU2001297571A1 (en) Detection and treatment of prostate cancer
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types
AU2002366712A8 (en) Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis